Overview
Spherix’s coverage of the atopic dermatitis market focuses on the monumental shift in the treatment paradigm, particularly the expansion of biologics and JAK inhibitors.
Services Available
Trending market evolution
Atopic Dermatitis (US) - quarterly, n=100
Atopic Dermatitis (EU) - semiannual, n=250
Exploring the patient journey
Moderate to Severe Atopic Dermatitis (US) - n=1,000 patient charts
Moderate to Severe Atopic Dermatitis (EU) - n=1,250 patient charts
Benchmarking new brand performance
Abrocitinib (Pfizer) in Atopic Dermatitis (US)*
Olumiant (Lilly) in Atopic Dermatitis (US)*
Rinvoq (AbbVie) in Atopic Dermatitis (US)*
Ruxolitinib (Incyte) in Atopic Dermatitis (US)*
Tralokinumab (LEO) in Atopic Dermatitis (US)*
*Pending approvals and launch
Gauging impact of disruptive events
Multi-Specialty Impact of COVID-19 (US)